Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Subscribe To Our Newsletter & Stay Updated
